Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer

Evaluate the impact of 18F-FDG-PET-CT on the staging of patients with muscle invasive bladder cancer. Based on the results of 2 18F-FDG-PET-CT's patients are stratified in non-metastatic, oligometastatic and polymetastatic bladder cancer patients and the treatment is adapted accordingly to improve overall survival.

Trial Details

NCT ID
NCT04724928
Phase
PHASE2
Sponsor
University Hospital, Ghent
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • Metastasis directed therapy (MDT)
  • Immunotherapy
  • Standard of care
Locations (sample)
  • Ghent, Belgium|51.05,3.71667

Key Eligibility Criteria

  • Histopathology-proven MIBC on TURb or ≥ T3 on conventional imaging treated with MIBC radical treatment
  • T1-4 N0-3 M0 MIBC on conventional imaging (thoracic CT and abdominopelvic CT/ MRI)
  • Age \> 18 years
  • Willingness to undergo 18F-FDG-PET-CT

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →